Product Search
We provide safer and differentiated healthcare products to customers
by combining medical technologies.
PRODUCT
Suvazet Tab. 10/10mg
Print
product information
Suvazet Tab. 10/10mg
| Classification | Ethical the Counter(ETC) |
|---|---|
| Major Ingredients | Rosuvastatin / ezetimibe |
| Efficacy/Effectiveness | Primary hypercholesterolemia |
| Appearance | White to almost white round film coating |
product information
Information
1. Raw materials and quantity: 1 tablet
[Active Ingredient] Rosuvastatin calcium (In-house) ... ... .5.2 mg (5 mg as rosuvastatin)
Ezetimibe ... ... ... ... ... ... ... ... ... ... ... ... 10.0 mg
[Additives - derived from animals] Lactose hydrate (derived from cow's milk)
[Other additives] Microcrystalline cellulose, butylhydroxyanisole, magnesium stearate, opaque white(03B28796), carnauba wax, croscarmellose sodium, hydroxypropylcellulose
2. DOSAGE AND ADMINISTRATION: Administer this medicine once a day, regardless of diet.
3. Storage method: Storage in airtight container at room temperature (1 ~ 30 ℃)
4. Packing unit: 15 tablets / blister ⅹ2
5. Expiration date: 24 months from date of manufacture
[Active Ingredient] Rosuvastatin calcium (In-house) ... ... .5.2 mg (5 mg as rosuvastatin)
Ezetimibe ... ... ... ... ... ... ... ... ... ... ... ... 10.0 mg
[Additives - derived from animals] Lactose hydrate (derived from cow's milk)
[Other additives] Microcrystalline cellulose, butylhydroxyanisole, magnesium stearate, opaque white(03B28796), carnauba wax, croscarmellose sodium, hydroxypropylcellulose
2. DOSAGE AND ADMINISTRATION: Administer this medicine once a day, regardless of diet.
3. Storage method: Storage in airtight container at room temperature (1 ~ 30 ℃)
4. Packing unit: 15 tablets / blister ⅹ2
5. Expiration date: 24 months from date of manufacture
Details
■ Precautions for use
1. Warning
Rarely, rhabdomyolysis with secondary acute renal failure by myoglobinuria has been rarely reported in rosuvastatin and other drugs of the same family. Thus, it is possible that the risk of secondary renal failure (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, uncontrolled Patients with seizures that do not have a history of seizures should temporarily suspend treatment or discontinue therapy.
1. Warning
Rarely, rhabdomyolysis with secondary acute renal failure by myoglobinuria has been rarely reported in rosuvastatin and other drugs of the same family. Thus, it is possible that the risk of secondary renal failure (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, uncontrolled Patients with seizures that do not have a history of seizures should temporarily suspend treatment or discontinue therapy.